Gw Pharmaceuticals Share Discussion Threads

[liquidkid] 24/11/2016 13:10

This is from GWP:
"the time is right to reduce the complexity and expense of a dual listing.
leading to a further reduction in the proportion of shares held and traded through AIM.
"Prior to that decision the BOD considered transfer from AIM to the Official List of the UK Listing Authority and to trading on the LSE's main market."

A few facts that are quite pertinent to this.

- Investors buying GWP did not pay Stamp Duty. Yet by having a dual listing i.e. listed on NASDAQ technicaly should have. The waiving of stamp duty encourages investors to invest in AIM

-The 1 year average daily volume in the UK was a healthy 477,000 shares a day. It has increased over the year to 650,000 now over the last month.

-It is cheap and easy to list on AIM - Companies only have to pay an annual fee of £6,500

IMO, The BOD have shown total and utter contempt for UK investors.

[nodding] 23/11/2016 21:38

ADR holders have voting rights. We will have to wait for the agm announcement

[cauchmer] 23/11/2016 17:29

I'm a bit miffed at AJ Bell:

I acknowledge that back in October I did receive secure messages asking me (separately) to elect what I wanted to do with my direct holding in GW (the residue of my original EIS investment in 2001) and with my much more substantial holding in my Sipp with Bell, asking for a response by yesterday.

The beef: NO REMINDERS. No email. No phone call. No follow up secure message.

In consequence I now find I have a lot of ADRs fully ten days before the UK de-listing from AIM.

I'm sure we've all observed the downward spiral this week and I was certainly contemplating possible last minute transaction/s in the next week on my UK holding.

Seems to me that Bell for their own administrative convenience elected to convert all that they are holding, without recourse, many days before the deadline.

But I guess I really hold Justin to account for holding this inconvenient pistol to our head.

PS: Where will the AGM be held in March and will we be eligible to attend?

[randompoint] 23/11/2016 14:11

essential - I think unremarkable in the run up to a big Dec that there's volatility. We're not that far off the NASDAQ biotech components on a 1 month view.

[essential] 23/11/2016 09:03

Any ideas for the recent weakness?

[liquidkid] 22/11/2016 16:42

Wolf of Weed Street Notes that Short interest is at All time high: 2.5 million shares worth a quarter of a billion dollars. Will take 7 trading Days To Cover.

And the competition is jostling at the Gate:

Another Phase 3 Orphan Drug Status for Dravet.
Zogenix, Inc. ZGNX $12.45 Mkt cap 308.65M
ZX008 - fenfluramine (3-trifluoromethyl-N-ethylamphetamine) The drug increases the level of serotonin, is reported to be dysphoric, "unpleasantly lethargic", used recreationally at high doses ranging between 80 and 400 mg, which have been described as producing euphoria, amphetamine-like effects,

Majority of physicans 'Strongly Recommend' potential. This compound could be a holy grail game changer for this syndrome - US Neurologist.

Estimated Study Completion Date:April 2017

[liquidkid] 22/11/2016 09:56

I like the willow bark analogy.

Say you stumble upon a bunch of bare footed yurt dwelling willow bark chewers deep in the jungles of East Scarfolk.
If you ask the question "why are you chewing that willow bark you got there?"
the answer would be "to cure the headaches, man."
Why not use aspirin?
"No way man, that's Big Pharma...Bad Karma. Dude."
So you leave the aspirin with them and come back in a 100 years time.
Guess what, they're still chewing willow bark.
You pull out a packet of willow bark infused chews.
Here try this, its also good for what few teeth you have left.
"No way man, that's Big Pharma...Bad Karma. Dude."

[nodding] 21/11/2016 16:27

Sounds like you will not be buying GW shares

[etarip] 21/11/2016 07:34

WengerB
Thanks for your prompt clarification.

[nodding] 20/11/2016 16:31

Back in post 8732 3rd eye gave us a piece of the Morgan Stanley broker note. Of particular interest to me were the references to off-label use and a "broad label for refractory patients". These things also appear in the Golman Sachs note issued last month, which, I am reliably informed, support their M&A value, $349.

That figure is based on estimated 2020 earnings x 11. Eleven it seems, is a median found from a list of pharma takeovers. More interesting is how they find their figures of estimated income. These are based on a label expected to cover Dravet and LGS, and other pediactric epilepsies which have atonic/clonic seizures (ie a broad label), plus off-label sales. The note discusses off-label use at some length and they have an empirical basis for their projection of 51% (51% of total sales; being $816m out of $1.6bn). No adult off-label sales are included. Adult use is discussed per the Expanded Access Programme, but no value is assigned to possible sales. I wonder myself, what will happen to the 17 year old Dravet patient on Epidiolex who becomes 18?

No value too is assigned to the pipeline. Both the GS 12 month target $189 and the M&A value $349 are derived solely from pediactric use: on label and off. As such I think one might see these figures as likely understated.

Perhaps the adult use aspect is too difficult to assess, or as I prefer to think, inclusion of an estimate would produce a target value that looks ridiculously huge.

[neilrr] 18/11/2016 17:45

Stoners will be stoners.

[bulltradept] 18/11/2016 16:53

I phoned up my broker iii and they would take orders over the phone but I couldn't deal on line, no one seemed to know why or were really interested in finding out, gave the lame excuse of he delisting, which according to the RNS is incorrect.

Oh well.

[abcd1234] 18/11/2016 15:52

You can on Barx (barclays)... can get online quotes for sells... but struggling to get any quote for a Buy

[bulltradept] 18/11/2016 15:46

Currently can't trade GWP on line! No idea why, but could through the broker.

[abcd1234] 18/11/2016 14:47

5% spike down stateside... any info as to why ??...ta

[nodding] 15/11/2016 14:06

Re: the fate of this message board/BB/thread -

Dear ...

Thank you for contacting ADVFN.

The de-listing of this company from AIM will not create any problem to the BB's thread linked to this epic, the thread will remain active and accessible.
Kind regards,
Andrew
Customer Support